Coferon
Coferon employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD65—98m (Dealroom.co estimates Jul 2012.)
Town of Brookhaven New York (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $7.1m | Debt | |
| N/A | $3.0m | Early VC | |
| N/A | $217k | Debt | |
$12.0m | Series B | ||
| N/A | $1.0m | Debt | |
| N/A | $4.0m | Debt | |
| N/A | $1.0m | Debt | |
| Total Funding | CAD20.5m | ||
Related Content
Recent News about Coferon
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.